Combined locoregional-immunotherapy for liver cancer.
Cell death
Locoregional therapy
Radiofrequency ablation
T cell
Tumour immunology
Journal
Journal of hepatology
ISSN: 1600-0641
Titre abrégé: J Hepatol
Pays: Netherlands
ID NLM: 8503886
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
17
10
2018
revised:
23
01
2019
accepted:
26
01
2019
pubmed:
10
2
2019
medline:
25
11
2020
entrez:
10
2
2019
Statut:
ppublish
Résumé
Locoregional therapies are commonly used to treat patients with hepatocellular carcinoma. It has been noted for many years that locoregional therapies may have additional systemic effects other than simple tumour elimination. Immunological "side effects" have been described in response to locoregional therapies in animal studies and in patients. With the advent of immunotherapy for hepatocellular carcinoma, there is increasing interest in determining the best way to combine immunotherapy with locoregional therapies. Herein, we provide a compact summary of answered and unanswered questions in the field, including: What animal model is best suited to test combined immune-locoregional treatments? How does tumour cell death affect immune responses? What type of immune responses have been observed in patients treated with different types of locoregional therapies? What can be surmised from the results of the first study testing the combination of locoregional therapy with immune checkpoint blockade? Finally, we discuss the outlook for this rapidly growing area of research, focussing on the issues which must be overcome to bridge the gap between interventional radiology and cancer immunology.
Identifiants
pubmed: 30738077
pii: S0168-8278(19)30074-1
doi: 10.1016/j.jhep.2019.01.027
pmc: PMC6462230
mid: NIHMS1520990
pii:
doi:
Substances chimiques
CTLA-4 Antigen
0
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
999-1007Subventions
Organisme : Intramural NIH HHS
ID : Z99 CA999999
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA CL040015-10
Pays : United States
Organisme : Intramural NIH HHS
ID : ZID BC011242-10
Pays : United States
Informations de copyright
Published by Elsevier B.V.
Références
Cancer Res. 2004 Jun 1;64(11):4024-9
pubmed: 15173017
Minim Invasive Ther Allied Technol. 2017 Dec;26(6):331-337
pubmed: 28417678
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
Cancer Res. 2003 Oct 1;63(19):6496-500
pubmed: 14559842
Liver Int. 2015 May;35(5):1590-6
pubmed: 24836705
J Vasc Interv Radiol. 2015 Aug;26(8):1229-37
pubmed: 25863596
J Immunother. 2008 Apr;31(3):271-82
pubmed: 18317360
Int J Clin Exp Pathol. 2017 Aug 01;10(8):8715-8720
pubmed: 31966730
Cancer Immunol Res. 2017 Oct;5(10):832-838
pubmed: 28851692
J Clin Invest. 2013 Nov;123(11):4755-68
pubmed: 24216478
Radiology. 2009 Apr;251(1):58-66
pubmed: 19251937
Cardiovasc Intervent Radiol. 2017 Aug;40(8):1185-1195
pubmed: 28283704
J Hepatol. 2017 Mar;66(3):545-551
pubmed: 27816492
Tumour Biol. 2012 Dec;33(6):2401-9
pubmed: 22965881
Cytokine. 2013 Nov;64(2):516-22
pubmed: 24035756
Trends Immunol. 2005 Oct;26(10):512-7
pubmed: 16109501
Nat Rev Cancer. 2006 Jul;6(7):535-45
pubmed: 16794636
Gut. 2016 Jan;65(1):134-43
pubmed: 25524262
Clin Cancer Res. 2009 Aug 1;15(15):4875-84
pubmed: 19638464
J Immunol. 2007 Feb 1;178(3):1914-22
pubmed: 17237442
Mol Med Rep. 2015 Oct;12(4):6065-71
pubmed: 26239573
J Hepatol. 2017 Sep 18;:
pubmed: 28923358
Br J Cancer. 2006 Oct 9;95(7):896-905
pubmed: 16953240
Int J Hyperthermia. 2018 Nov;34(7):934-942
pubmed: 29631466
Annu Rev Immunol. 2013;31:51-72
pubmed: 23157435
Gut. 2019 Feb;68(2):335-346
pubmed: 29440463
BMC Cancer. 2018 Jan 31;18(1):117
pubmed: 29386009
Acta Biochim Biophys Sin (Shanghai). 2016 Apr;48(4):371-7
pubmed: 26922319
J Cancer Res Ther. 2018 Jan;14(1):40-45
pubmed: 29516957
Minim Invasive Ther Allied Technol. 2017 Aug;26(4):207-211
pubmed: 28635405
Proc Natl Acad Sci U S A. 2018 Oct 16;115(42):E9879-E9888
pubmed: 30287485
Cancer Res. 2006 Jul 15;66(14):7285-92
pubmed: 16849578
Trends Mol Med. 2008 Apr;14(4):141-51
pubmed: 18353726
Int J Cancer. 2003 Jan 10;103(2):205-11
pubmed: 12455034
Clin Cancer Res. 2013 Dec 15;19(24):6678-85
pubmed: 24030702
Onco Targets Ther. 2016 May 17;9:2835-44
pubmed: 27274279
Radiology. 2015 Aug;276(2):426-32
pubmed: 26203709
Cancer Immunol Immunother. 2013 Aug;62(8):1421-30
pubmed: 23764929
BMC Res Notes. 2018 Apr 24;11(1):251
pubmed: 29690935
Nat Rev Gastroenterol Hepatol. 2018 Sep;15(9):536-554
pubmed: 29904153
Cancer Immunol Immunother. 2018 May;67(5):843-853
pubmed: 29500633
Cancer Res. 2012 Jan 15;72(2):430-9
pubmed: 22108823
Nat Rev Cancer. 2014 Mar;14(3):199-208
pubmed: 24561446
J Vasc Interv Radiol. 2016 Oct;27(10):1561-8
pubmed: 27084711
Cell Mol Life Sci. 2015 Jan;72(2):273-83
pubmed: 25274062
Nature. 2018 Oct;562(7725):69-75
pubmed: 30209397
Cancer Cell. 2015 Dec 14;28(6):690-714
pubmed: 26678337
PLoS One. 2012;7(5):e37266
pubmed: 22615958
PLoS One. 2013;8(4):e60444
pubmed: 23565248
Hepatobiliary Pancreat Dis Int. 2015 Aug;14(4):361-6
pubmed: 26256079
Nat Commun. 2016 Oct 21;7:13193
pubmed: 27767031
Int J Oncol. 2012 Jan;40(1):63-70
pubmed: 21922136
Hepatology. 2013 Apr;57(4):1448-57
pubmed: 23174905
World J Gastroenterol. 2014 Nov 21;20(43):15955-64
pubmed: 25473149
Eur J Cancer. 2005 Sep;41(13):1911-22
pubmed: 16084718
Infect Agent Cancer. 2016 Dec 1;11:62
pubmed: 27980609
Cell Biochem Biophys. 2015 Dec;73(3):787-92
pubmed: 27259326
Nanoscale. 2016 Feb 21;8(7):4324-39
pubmed: 26837265
Cardiovasc Intervent Radiol. 2011 Aug;34(4):824-32
pubmed: 21671151
Oncoimmunology. 2012 Oct 1;1(7):1017-1026
pubmed: 23170250
J Hepatol. 2013 Jul;59(1):81-8
pubmed: 23466307
Diagn Interv Radiol. 2014 Jul-Aug;20(4):335-40
pubmed: 24834491
Gastroenterology. 2008 Jul;135(1):234-43
pubmed: 18485901
J Vasc Interv Radiol. 2017 Oct;28(10):1467-1471
pubmed: 28941521